KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Income from Continuing Operations (2016 - 2025)

Teva Pharmaceutical Industries (TEVA) has disclosed Income from Continuing Operations for 10 consecutive years, with 470000000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Income from Continuing Operations rose 270.29% year-over-year to 470000000.0, compared with a TTM value of 1539000000.0 through Dec 2025, up 178.52%, and an annual FY2025 reading of 1403000000.0, up 171.58% over the prior year.
  • Income from Continuing Operations was 470000000.0 for Q4 2025 at Teva Pharmaceutical Industries, down from 646000000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 646000000.0 in Q3 2025 and bottomed at 1334000000.0 in Q4 2022.
  • Average Income from Continuing Operations over 5 years is 156750000.0, with a median of 46000000.0 recorded in 2021.
  • The sharpest move saw Income from Continuing Operations surged 294.34% in 2021, then crashed 1286.59% in 2022.
  • Year by year, Income from Continuing Operations stood at 151000000.0 in 2021, then crashed by 783.44% to 1334000000.0 in 2022, then surged by 132.38% to 432000000.0 in 2023, then tumbled by 163.89% to 276000000.0 in 2024, then soared by 270.29% to 470000000.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for TEVA at 470000000.0 in Q4 2025, 646000000.0 in Q3 2025, and 203000000.0 in Q2 2025.